CytoSorbents Corporation (CTSO), a critical care focused company using blood purification to treat life-threatening illnesses in the intensive care unit, was recently featured in the article "Blood Purification Device for ICU Patients Seeks to Treat Root Cause of Sepsis" on May 24, 2013 in MedCity News.
Highlights from the MedCity News Article:
The cost of treating sepsis was $14.6 billion in 2008, according to the Centers for Disease Control and Prevention.
CytoSorb®, the Company's flagship blood purification technology, targets the prevention or treatment of organ failure, the root cause of death in sepsis and many other critical illnesses commonly treated in the intensive care unit (ICU).
Organ failure is caused by an excessive immune response to an infection or injury. CytoSorb® works by directly removing cytokines, toxins, and other inflammatory substances that are driving this response.
CytoSorb® is approved in all countries of the European Union and is now generating commercial sales in Germany, Austria, Switzerland and the United Kingdom.
CytoSorb® can be used "on-label" in critically-ill patients for many medical issues, including sepsis, pancreatitis, liver failure and complications of surgery.
The Company plans to pursue a sepsis pivotal trial in the U.S. in early 2014, with the goal of achieving U.S. regulatory approval for CytoSorb® after several years.
Highlights approximately $5 million in grant money awarded to the Company by agencies of the U.S. Department of Defense such as DARPA and the U.S. Army.